The use of the fusion product of dendritic cells and tumor cells as a tumor vaccine represents one of the most promising approaches for cancer immunotherapy.After the development of a highly novel technology that instantly isolates the hybrids (dendritomas) from the fusion mixture of DCs and tumor cells, we have carried out extensive pre-clinical animal studies and toxicology studies to show the efficacy and safety of such a dendritoma vaccine.